Amaranth Medical On Track to Complete Enrollment in RENASCENT-II Study of 120-Micron APTITUDE™ Sirolimus-Eluting Bioresorbable Scaffold in May
May 18, 2016 03:01 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA , May 18, 2016 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company, provided a clinical update on its ongoing RENASCENT-II study of its novel APTITUDE™...
Amaranth Medical Reports Findings from Two FORTITUDE Bioresorbable Scaffold Studies at EuroPCR 2015
May 18, 2015 15:12 ET
|
Amaranth Medical, Inc.
Mountain View, CA, May 18, 2015 (GLOBE NEWSWIRE) -- Amaranth Medical, a
privately held medical device company, announced plans to report
clinical results from the Company's ongoing trial of...
Amaranth Medical Reports Positive Safety and Feasibility Findings for the FORTITUDE(TM) Bioresorbable Scaffold
October 28, 2013 08:00 ET
|
Amaranth Medical, Inc.
MOUNTAIN VIEW, CA, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Amaranth Medical, a privately held medical device company,
presented positive six-month angiographic results from its
first-in-human study...